Table 2. Patient Demographics, HHV8 DNA and Antibody Positivity, and clinical Details for participants with biopsy proven KS.
| Pt | Sex | HHV8 Antibody | HHV8 DNA | ART at Time of Sampling | Clinical Details | Chemotherapy |
|---|---|---|---|---|---|---|
| 1a | M | + | + | Yesb | Disseminated KS (skin, lung) | Paclitaxel/Doxorubicin |
| 2 | M | + | + | Yes | Extensive disseminated KS (skin, viscera, lung), | Paxlitaxel |
| 3a | M | + | + | Yes | Disseminated cutaneous KS | Doxorubicin |
| 4 | M | + | - | Yes | Rectal mass and lymph node KS | Doxorubicin |
| 5 | M | + | + | Yes | Disseminated KS (skin, mucosa, pleura, lymph nodes) | Doxorubicin |
| 6a | M | + | + | Yes | Cutaneous KS and concomitant MCD | Rituximab |
Pt = participant; KS = Kaposi’s Sarcoma; MCD = multicentric Castleman disease
a longitudinal data on detectable HHV8 levels were available
b Patient started ART after baseline, pre-chemotherapy sampling